Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-04-26
2011-04-26
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S234000
Reexamination Certificate
active
07932253
ABSTRACT:
N-(1-Aza-bicyclo[2.2.2]oct-3-yl)-4-(6,9-difluoro-3-oxo-1,3-dihydro-pyrazolo[4,3-c]cinnolin-2-yl)-benzamide is a CD80 antagonist, useful in the treatment of diseases which benefit from immuno-inhibition.
REFERENCES:
patent: 3576637 (1971-04-01), Suga et al.
patent: 4591589 (1986-05-01), Gasc et al.
patent: 5061705 (1991-10-01), Wuest et al.
patent: 7276505 (2007-10-01), Matthews
patent: 7566713 (2009-07-01), Mathews
patent: 7598247 (2009-10-01), Matthews
patent: 2007/0213345 (2007-09-01), Matthews
patent: 2009/0062289 (2009-03-01), Matthews
patent: 2009/0221590 (2009-09-01), Matthews
patent: 2009/0312334 (2009-12-01), Matthews
patent: 0255892 (1988-02-01), None
patent: 0269030 (1988-06-01), None
patent: 629412 (1949-09-01), None
patent: 97/34893 (1997-09-01), None
patent: 99/00391 (1999-01-01), None
patent: 03/004485 (2003-01-01), None
patent: WO 03/004495 (2003-01-01), None
patent: 2004/048378 (2004-06-01), None
patent: 2004/055014 (2004-07-01), None
patent: WO 2004/081011 (2004-09-01), None
patent: WO 2004/081011 (2004-09-01), None
patent: WO 2005/116033 (2005-12-01), None
patent: WO 2007/096588 (2007-08-01), None
Griesser, Ch. 8, The Importance of Solvates (pp. 211-230), in the text, Polymorphism: In the Pharmaceutical Industry, Hilfiker, 2006.
Brittain, Chapter V of Polymorphism in Pharmaceutical Solids, 1999, pp. 126-127.
MediGene, http://www.medigene.de/englisch/ProjektRH.php, downloaded Aug. 28, 2009.
ClinicalTrials.gov, http://clinicaltrials.gov/ct2/show/NCT00704119, last updated Nov. 4, 2008, downloaded Mar. 10, 2010.
D.E. Ames et al: “Preparation of cinnoline-3,4-dicarbonitrile and -dicarboxylic acid”, Tetrahedron, vol. 37, No. 14, 1981, pp. 2489-2491, XP002333094.
Appel & Brossart, “Development of Novel Compounds to Treat Autoimmune and Inflammatory Diseases and Graft Versus Host Reactions,” Endocrin. Metab. Immune Disord. Drug Targets 7, 93-97, 2007.
Brumeanu et al., “Down-regulation of autoreactive T-cells by HMG CoA reductase inhibitors,” Clin. Immunol. 119, 1-12, 2006.
Chitale and Moots, “Abatacept: the first T lymphocyte co-stimulation modulator, for the treatment of rheumatoid arthritis,” Expert. Opin. Biol. Ther. 2008; 8:115-122.
Choy, “T Cells in Psoriatic Arthritis,” Curr. Rheumatol. Rep. 6, 437-41, 2007.
Cope et al., “The central role of T cells in rheumatoid arthritis,” Clin. Exp. Rheumatol. 24, 4-11, 2007.
Dubey et al., “Costimulatory requirements of naive CD4+ T cells. ICAM-1 or B7-1 can costimulate Naïve CD4 T Cell Activation but Both Are Required for Optimum Response,”J Immunol.1995; 155: 45-57.
Gimmi et al., “Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation,” Proc. Nat. Acad. Sci. USA 90, pp. 6586-6590, Jul. 1993.
Kobata et al., “Role of costimulatory molecules in autoimmunity,” Rev. Immunogenet. 2, 74-80, 2000.
Kristensen et al., “The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review,” Scand. J. Rheumatol. 2007; 36:411-417.
Linsley et al., “Binding of the B Cell Activation Antigen B7 to CD28 Costimulates T Cell Proliferation and Interleukin 2 mRNA Accumulation,” J. Exp. Med. 173, 721-30, Mar. 1991.
Mallone & Endert, “T Cells in the Pathogenesis of Type 1 Diabetes,” Curr. Diab. Rep. 8, 101-06, 2008.
Suresh et al., “Role of CD28-B7 Interactions in Generation and Maintenance of CD8 T Cell Memory,” The Journal of Immunology, 2001, 167: 5565-5573.
Weiss et al., .“Role of CD28-B7 Interactions in Generation and Maintenance of CD8 T Cell Memory,” Neuroimmunol. 191, 79-85, 2007.
Medigene Press Release, “RhuDex(TM) Clinical Development to Continue Following Feedback from Regulatory Authorities,” Oct. 5, 2009.
Collins et al., “The interaction properties of costimulatory molecules revisited,”Immunity, vol. 17, pp. 201-210, 2002.
Lenschow et al., “CD28/B7 system of T cell costimulation,”Annu. Rev. Immunol., vol. 14, pp. 233-258, 1996.
Byun et al., “Preparation of polymer-bound pyrazoloneactive esters for combinatorial chemistry,” Tetrahedron Letters, vol. 44, pp. 8063-8067, Oct. 2003.
Huxley et al., “High-affinity small molecule inhibitors of T cell costimulation,” Chem. Biol., vol. 11, pp. 1651-1658, 2004.
Lukes et al., “Oral feeding with pig peripheral lymphocytes decreases the xenogeneic delayed type hypersensitivity reaction in galactosyltransferase knockout mice,” Abstract, Transplant Proc., vol. 37, No. 8, pp. 3327-3331, 2005.
Ninomiya et al., “Phosphorus in Organic Synthesis—VII,” Tetrahedron, vol. 30, No. 4, pp. 2151-2157, 1974.
Salomon et al., B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes; Immunity, vol. 12, pp. 431-440, 2000.
Saxena et al., “Abrogation of DTH response and mitogenic lectin- and alloantigen-induced activation of lymphocytes by calcium inhibitors TMB-8 and BAPTA-AM,” Immunol. Lett., vol. 101, No. 1, pp. 60-64, Oct. 15, 2005.
Strieth et al., “Paclitaxel encapsulated in cationic liposomes increases tumor microvessel leakiness and improves therapeutic efficacy in combination with Cisplatin,” Clin Cancer Res., vol. 14, No. 14, pp. 4603-4611, 2008.
Strieth et al., “Tumor-selective vessel occlusions by platelets after vascular targeting chemotherapy using paclitaxel encapsulated in cationic liposomes,” Int J Cancer, vol. 122, No. 2, pp. 452-460, 2008.
Weiss et al., “CD8+ T cells in inflammatory demyelinating disease,” J Neuroimmunol., vol. 191, Nos. 1-2, pp. 79-85, Nov. 2007.
West, “Solid state chemistry and its applications,” Wiley & Sons, New York, book Chapter 10, pp. 358-359, 1988.
Heller, “Zur Kenntnis der Arylamide aromatischer Carbon- und Sulfosäuren,” J. Prakt. Chemie 121, 193-203, 1929.
Michaelis, “Über die Anhydride der 1-Phenyl-5- und -3-pyrazolon-o-carbonsäuren,” 129-212, Justus Liebigs Annalen der Chemie 373, 129-238, 1910.
Picciola et al., “Composti Eterociclici a Potenziale Attivita Antiinflammatoria Contenenti II Residuo di un Acido 4-Amminofenilalcanoico,” Il Farmaco 39, 371-378, 1984 (English abstract).
Banner & Witcoff , Ltd.
Jaisle Cecilia M
Medigene AG
Wilson James O
LandOfFree
Immunomodulating oxopyrrazolocinnolines as CD80 inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunomodulating oxopyrrazolocinnolines as CD80 inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunomodulating oxopyrrazolocinnolines as CD80 inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2729854